242 related articles for article (PubMed ID: 12646035)
1. A comparison of physiochemical property profiles of development and marketed oral drugs.
Wenlock MC; Austin RP; Barton P; Davis AM; Leeson PD
J Med Chem; 2003 Mar; 46(7):1250-6. PubMed ID: 12646035
[TBL] [Abstract][Full Text] [Related]
2. Time-related differences in the physical property profiles of oral drugs.
Leeson PD; Davis AM
J Med Chem; 2004 Dec; 47(25):6338-48. PubMed ID: 15566303
[TBL] [Abstract][Full Text] [Related]
3. Characteristic physical properties and structural fragments of marketed oral drugs.
Vieth M; Siegel MG; Higgs RE; Watson IA; Robertson DH; Savin KA; Durst GL; Hipskind PA
J Med Chem; 2004 Jan; 47(1):224-32. PubMed ID: 14695836
[TBL] [Abstract][Full Text] [Related]
4. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
Kuentz M; Imanidis G
Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
[TBL] [Abstract][Full Text] [Related]
5. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development.
Gill AL; Verdonk M; Boyle RG; Taylor R
Curr Top Med Chem; 2007; 7(14):1408-22. PubMed ID: 17692029
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based formulations for oral administration of poorly water-soluble drugs.
Mu H; Holm R; Müllertz A
Int J Pharm; 2013 Aug; 453(1):215-24. PubMed ID: 23578826
[TBL] [Abstract][Full Text] [Related]
7. Molecular inflation, attrition and the rule of five.
Leeson PD
Adv Drug Deliv Rev; 2016 Jun; 101():22-33. PubMed ID: 26836397
[TBL] [Abstract][Full Text] [Related]
8. Dependence of molecular properties on proteomic family for marketed oral drugs.
Vieth M; Sutherland JJ
J Med Chem; 2006 Jun; 49(12):3451-3. PubMed ID: 16759087
[TBL] [Abstract][Full Text] [Related]
9. The evolution of synthetic oral drug properties.
Proudfoot JR
Bioorg Med Chem Lett; 2005 Feb; 15(4):1087-90. PubMed ID: 15686918
[TBL] [Abstract][Full Text] [Related]
10. Absorption classification of oral drugs based on molecular surface properties.
Bergström CA; Strafford M; Lazorova L; Avdeef A; Luthman K; Artursson P
J Med Chem; 2003 Feb; 46(4):558-70. PubMed ID: 12570377
[TBL] [Abstract][Full Text] [Related]
11. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?
Giordanetto F; Kihlberg J
J Med Chem; 2014 Jan; 57(2):278-95. PubMed ID: 24044773
[TBL] [Abstract][Full Text] [Related]
12. The role of ligand efficiency metrics in drug discovery.
Hopkins AL; Keserü GM; Leeson PD; Rees DC; Reynolds CH
Nat Rev Drug Discov; 2014 Feb; 13(2):105-21. PubMed ID: 24481311
[TBL] [Abstract][Full Text] [Related]
13. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.
Bayliss MK; Butler J; Feldman PL; Green DV; Leeson PD; Palovich MR; Taylor AJ
Drug Discov Today; 2016 Oct; 21(10):1719-1727. PubMed ID: 27423371
[TBL] [Abstract][Full Text] [Related]
14. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
Zuegg J; Cooper MA
Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
[TBL] [Abstract][Full Text] [Related]
15. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
16. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
Doak BC; Over B; Giordanetto F; Kihlberg J
Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical profiling in drug discovery.
Kerns EH; Di L
Drug Discov Today; 2003 Apr; 8(7):316-23. PubMed ID: 12654544
[TBL] [Abstract][Full Text] [Related]
18. The physicochemical challenges of designing multiple ligands.
Morphy R; Rankovic Z
J Med Chem; 2006 Aug; 49(16):4961-70. PubMed ID: 16884308
[TBL] [Abstract][Full Text] [Related]
19. Influence of molecular properties on oral bioavailability of lipophilic drugs - mapping of bulkiness and different measures of polarity.
Kuentz MT; Arnold Y
Pharm Dev Technol; 2009; 14(3):312-20. PubMed ID: 19235630
[TBL] [Abstract][Full Text] [Related]
20. Poorly soluble marketed drugs display solvation limited solubility.
Bergström CA; Wassvik CM; Johansson K; Hubatsch I
J Med Chem; 2007 Nov; 50(23):5858-62. PubMed ID: 17929794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
